Last updated on September 2020

A Phase II Study in Patients With Alopecia Areata


Brief description of study

This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.

Detailed Study Description

The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 3 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

Clinical Study Identifier: NCT04346316

Find a site near you

Start Over

Novatrials

Kogarah, Australia
  Connect »

Quest Dermatology Research

Northridge, CA United States
  Connect »

Skin Search of Rochester, Inc

Rochester, NY United States
  Connect »

The Skin Wellness Center

Knoxville, TN United States
  Connect »

Progressive Clinical Research

San Antonio, TX United States
  Connect »

Sinclair Dermatology

East Melbourne, Australia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.